Log in

NASDAQ:TARA - Verona Pharma Stock Price, Forecast & News

$28.92
+1.22 (+4.40 %)
(As of 02/28/2020 08:00 AM ET)
Today's Range
$25.40
Now: $28.92
$30.07
50-Day Range N/A
52-Week Range
$8.80
Now: $28.92
$157.60
Volume11,000 shs
Average Volume22,832 shs
Market Capitalization$168.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.47
ArTara Therapeutics, Inc. develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TARA
CUSIPN/A
CIKN/A
Phone781-890-0102

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($2.25) per share

Profitability

Net Income$-20,730,000.00

Miscellaneous

EmployeesN/A
Market Cap$168.89 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive TARA News and Ratings via Email

Sign-up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.


Verona Pharma (NASDAQ:TARA) Frequently Asked Questions

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "TARA."

When is Verona Pharma's next earnings date?

Verona Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Verona Pharma.

What price target have analysts set for TARA?

1 analysts have issued 1-year price targets for Verona Pharma's stock. Their forecasts range from $45.00 to $45.00. On average, they expect Verona Pharma's share price to reach $45.00 in the next twelve months. This suggests a possible upside of 55.6% from the stock's current price. View Analyst Price Targets for Verona Pharma.

What is the consensus analysts' recommendation for Verona Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verona Pharma.

Has Verona Pharma been receiving favorable news coverage?

News articles about TARA stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Verona Pharma earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Verona Pharma.

Are investors shorting Verona Pharma?

Verona Pharma saw a increase in short interest in February. As of February 14th, there was short interest totalling 7,300 shares, an increase of 10.6% from the January 30th total of 6,600 shares. Based on an average daily volume of 12,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 3.3% of the shares of the stock are short sold. View Verona Pharma's Current Options Chain.

Who are some of Verona Pharma's key competitors?

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Uber Technologies (UBER), TG Therapeutics (TGTX), AudioCodes (AUDC) and ACADIA Pharmaceuticals (ACAD).

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the folowing people:
  • Mr. Jesse Shefferman, Co-Founder & CEO
  • Dr. Julio Casoy, Chief Medical Officer
  • Dr. Jacqueline Zummo, VP and Head of R&D Operations

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (0.18%).

Which institutional investors are buying Verona Pharma stock?

TARA stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc..

How do I buy shares of Verona Pharma?

Shares of TARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Verona Pharma's stock price today?

One share of TARA stock can currently be purchased for approximately $28.92.

How big of a company is Verona Pharma?

Verona Pharma has a market capitalization of $168.89 million. The company earns $-20,730,000.00 in net income (profit) each year or ($46.00) on an earnings per share basis. View Additional Information About Verona Pharma.

What is Verona Pharma's official website?

The official website for Verona Pharma is http://www.proteontherapeutics.com/.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 200 WEST STREET, WALTHAM MA, 02451. The company can be reached via phone at 781-890-0102 or via email at [email protected]


MarketBeat Community Rating for Verona Pharma (NASDAQ TARA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  4 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  7
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe TARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: What are gap-down stocks?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel